PRF Technologies (PRFX) Cash & Equivalents (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Cash & Equivalents of $3.1 million for Q4 2025, down 26.66% year-on-year from $4.3 million in Q4 2024, and down 10.56% on a QoQ basis from $3.5 million in Q2 2025.
PRF Technologies (PRFX) Cash & Equivalents (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Cash & Equivalents for 7 consecutive years, with $3.1 million the latest figure, recorded in Q4 2025.
- Quarterly Cash & Equivalents fell 26.66% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 26.66% YoY) and the FY2025 annual result came in at $3.1 million, down 26.66% from the prior year.
- Cash & Equivalents declined to $3.1 million in Q4 2025 per PRFX's latest filing, from $3.5 million in the prior quarter.
- Over the last five years, Cash & Equivalents for PRFX reached as high as $19.4 million in Q1 2021 and fell as low as $2.8 million in Q2 2024.
- A 5-year average of $9.4 million and a median of $7.6 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2021 — Cash & Equivalents surged 3137.09% — and 2022, when it slumped 75.23%.
- Year by year, Cash & Equivalents stood at $16.5 million in 2021, then sank by 75.23% to $4.1 million in 2022, then soared by 95.95% to $8.0 million in 2023, then tumbled by 46.91% to $4.3 million in 2024, then decreased by 26.66% to $3.1 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $3.1 million, $3.5 million, and $4.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 3.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | 8.03 Mn |
| Sep 30, 2023 | 7.56 Mn |
| Jun 30, 2023 | 5.15 Mn |
| Mar 31, 2023 | 8.15 Mn |
| Dec 31, 2022 | 4.10 Mn |
| Sep 30, 2022 | 6.95 Mn |
| Jun 30, 2022 | 13.87 Mn |
| Mar 31, 2022 | 16.57 Mn |
| Dec 31, 2021 | 16.54 Mn |
| Sep 30, 2021 | 18.34 Mn |
| Jun 30, 2021 | 17.80 Mn |
| Mar 31, 2021 | 19.44 Mn |
| Dec 31, 2020 | 15.68 Mn |
| Sep 30, 2020 | 17.72 Mn |
| Jun 30, 2020 | 550,000.00 |